Part of the current knowledge about cannabinoids originates from the studies on the psychotropic effect of Cannabis sativa plant; however, its ancient therapeutic purpose is known about 2600 B.C. In the XIX century, the systematization of their therapeutic use described by Sir William Brooke O’Shaughnessy showed the potential of these compounds in the management of epilepsy, inflammation, and pain .
Pain is a common symptom of equine veterinary patients with chronic degenerative diseases. In these patients, the treatment of first choice are nonsteroidal anti-inflammatory drugs (NSAIDs); however, the prolonged use of NSAIDs produces diverse side effects, including gastric irritation and peptic ulcer. Hence, the identification of alternative treatments is crucial.
In this sense, recently, it has been proposed cannabinoids CB2 receptors as therapeutic targets for treatment of pain because these receptors look to confer antinociceptive properties but without the psychoactive side effects.
Therefore, the objective of this article was to contribute to understand the pharmacology of cannabinoid CB2 receptors and its potential utilization on equine veterinary patients with a chronic degenerative painful condition.
Note: All information on this page is for informational purposes only and is the property of the study organizer. CannaHorse makes no representation through the sharing of this material.